ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
The impact of palliative care consults on medicines optimisation for patients with cancer referred to hospice care at the end of life: a retrospective cohort study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Trends in prescriptions and factors associated with discontinuation of potentially inappropriate medications in elderly patients with advanced cancer at the end of life: A retrospective cohort study.Palliative care and social practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study evaluated the impact of Palliative Care Consults (PCC) on medicines optimisation in patients with cancer, focusing on deprescribing patterns and associated predictors.
methodsThis retrospective cohort study reviewed the medical records of patients with cancer admitted to an inpatient hospice unit between January 1 and December 31, 2022. Data were collected at hospice admission, first PCC assessment, and the day of death. Eligible patients had a life expectancy of ≤ six months, a Palliative Performance Scale (PPS) score ≤ 70%, and were prescribed at least one preventive medication at admission. Outcomes included medication burden (preventive medication use and polypharmacy), symptom control medication use, and potentially inappropriate medication (PIMs) use, assessed using OncPal criteria. PIM deprescribing patterns and predictors of successful deprescribing were analysed.
resultsAmong 321 patients (mean age 62.6 years; 60.1% female), the mean number of medications decreased from 7.87 at admission to 7.22 on the day of death (P < 0.001). Preventive medications decreased from 3.53 to 1.25, while symptom control medications increased from 4.34 to 5.98. PCC was associated with a significant PIM reduction (2.11 to 0.52; P < 0.001). Deprescribing was predominantly proactive at the first PCC assessment (61.3%) but reactive in later stages (89.6%). Male gender, absence of polypharmacy, and fewer than three PIMs at admission were significantly associated with successful deprescribing (P < 0.05).
conclusionsPCC was associated with improved medicines optimisation, though deprescribing remained reactive. Integration of structured, proactive deprescribing guidelines may enhance hospice care at the end of life.
Indexed as
Identifiers
40768088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.